Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

Journal of Clinical Pharmacology

Volumn 55, Issue 9, 2015, Pages 1012-1023

  Nguyen, Linh ^a   Holland, Jaymes ^a   Miles, Dale ^a   Engel, Caroline ^b   Benrimoh, Natacha ^b   O'Reilly, Terry ^b   Lacy, Steven ^a  

^a EXELIXIS INC   (United States)

^b CELERION   (United States)

Author keywords

cabozantinib; CYP2C8; CYP3A4; drug drug interaction; pharmacokinetics

Indexed keywords

CABOZANTINIB; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; KETOCONAZOLE; RIFAMPICIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANILIDE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

ADULT; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG CLEARANCE; ENZYME INHIBITION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; KIDNEY CARCINOMA; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PROTEINURIA; STEADY STATE; VOMITING; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; ENZYMOLOGY; HALF LIFE TIME; METABOLISM;

ANILIDES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP3A INDUCERS; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; KETOCONAZOLE; MICROSOMES, LIVER; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RIFAMPIN; THIAZOLIDINEDIONES;

EID: 84937676195     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.510     Document Type: Article

References (29)

1. COMETRIQ™ (cabozantinib) capsules. US Prescribing Information. Exelixis, Inc. November 2012.
2. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) for cabozantinib (COMETRIQ). 2012. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/203756Orig1s000ClinPharmR.pdf. Accessed July 14, 2014.
3. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI., A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014; 24 (10): 1508-1514.
4. Choueiri TK, Pal SK, McDermott DF, et al., A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014; 25 (8): 1203-1208.
5. Hauschke D, Steinijans VW, Diletti E, Burke M., Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992; 20 (5): 557-561.
6. Cabanillas ME, Brose MS, Ramies DA, et al., Anti-tumor activity observed in a cohort of patients (pts) with differentiated thyroid cancer (DTC) in a Phase 1 study of cabozantinib (XL184) [abstract 5547]. J Clin Oncol. 2012; 30 (suppl).
7. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT., Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 2003; 42 (9): 819-850.
8. US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry. Drug interaction studies-study design, data analysis, and implications for dosing and labeling. Draft Guidance. 2006.
9. Hunt CM, Watkins PB, Saenger P, et al., Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther. 1992; 51 (1): 18-23.
10. Watkins PB, Turgeon DK, Saenger P, et al., Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther. 1992; 52 (3): 265-273.
11. Micuda S, Sispera L, Hodac M, et al., Diurnal variation of 6beta-hydroxycortisol in cardiac patients. Physiol Res 2007; 56 (3): 307-313.
12. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE., Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol. 1999; 39 (5): 487-494.
13. Swaisland HC, Ranson M, Smith RP, et al., Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005; 44 (10): 1067-1081.
14. Bolton AE, Peng B, Hubert M, et al., Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol. 2004; 53 (2): 102-106.
15. Thomas-Schoemann A, Blanchet B, Bardin C, et al., Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014; 89 (1): 179-196.
16. Ohnhaus EE, Breckenridge AM, Park BK., Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol. 1989; 36 (1): 39-46.
17. Venkatakrishnan K, von Moltke LL, Greenblatt DJ., Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000; 38 (2): 111-180.
18. Chien JY, Lucksiri A, Ernest CS, 2nd, Gorski JC, Wrighton SA, Hall SD. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos. 2006; 34 (7): 1208-1219.
19. Oo C, Chen YC., The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol. 2009; 49 (3): 368-369; author reply 370.
20. Dutreix C, Peng B, Mehring G, et al., Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol. 2004; 54 (4): 290-294.
21. Pithavala YK, Tong W, Mount J, et al., Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs. 2012; 30 (1): 273-281.
22. Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D., Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol. 2013; 53 (9): 974-981.
23. US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry: in vivo drug metabolism/drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. 2012.
24. US Food and Drug Administration. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to restrict access to rosiglitazone-containing medicines including avandia, avandamet, and avandaryl. May 18, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm. Accessed July 14, 2014.
25. Kurzrock R, Sherman SI, Ball DW, et al., Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011; 29 (19): 2660-2666.
26. Escudier B, Eisen T, Stadler WM, et al., Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356 (2): 125-134.
27. Rini BI, Escudier B, Tomczak P, et al., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378 (9807): 1931-1939.
28. Motzer RJ, Hutson TE, Cella D, et al., Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369 (8): 722-731.
29. Motzer RJ, Hutson TE, Tomczak P, et al., Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27 (22): 3584-3590.